Glenmark Receives U.S. FDA Approval to Expand the Use of Ryaltris Nasal Spray for Children Aged 6 to Less Than 12 Years

Дата публикации: 21-07-2026 19:07:03

Elmwood Park, New Jersey, July 21, 2026: Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of Ryaltris (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Skyrizi (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease	0	13.95	26-06-2026
2	FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2	0	19.68	29-06-2026
3	FDA Approves Simtriyo (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)	0	12.21	24-07-2026
4	FDA Approves Gwyn Lo (norelgestromin and ethinyl estradiol) Once-Weekly Contraceptive Patch	0	12.8	29-07-2026
5	FDA Grants Accelerated Approval for Genglycos (pariglasgene brecaparvovec-opnr) Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia	0	13.83	19-08-2026
6	Tryngolza (olezarsen) Approved to Reduce Triglycerides and the Risk of Acute Pancreatitis in Patients with Severe Hypertriglyceridemia	0	8.04	24-06-2026
7	Xeomin Approved For Expanded Indication in Pediatric Upper Limb Spasticity Patients with Cerebral Palsy Following FDA Label Update	0	10.02	26-06-2026
8	Octapharma USA Announces Expanded FDA Approval of Wilate for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years	0	14.08	08-07-2026
9	FDA Approves Lytenava (bevacizumab-vikg) for the Treatment of Wet Age-Related Macular Degeneration	0	16.74	24-07-2026
10	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) as a Treatment for Wet AMD	0	10.76	16-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.57. Источник: www.drugs.com.